## IN THE CLAIMS

Please amend the claims as follows:

Claims 1-10 are canceled.

Claim 11 (New): Piperazine benzothiazole derivatives according to formula I

$$\begin{array}{c|c}
N & N \\
N &$$

as well as its tautomers, its geometrical isomers, its optically active forms as .

enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

R is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl heteroaryl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, acyl, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, sulfonyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyloxy, sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, sulfanyl, sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylamino and mixtures thereof;

 $R^1$  is selected from the group consisting of H, halogen, cyano, nitro, amino,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $C_1$ - $C_6$ -alkyl-aryl, aryl or heteroaryl,  $C_1$ - $C_6$ -alkyl-heteroaryl, -C(O)- $OR^2$ , -C(O)- $R^2$ , -C(O)- $NR^2R^2$ ,  $-(SO_2)R^2$  and mixtures thereof, with

 $R^2$  and  $R^2$  being independently selected from the group consisting of hydrogen,  $C_1$ - $\dot{C_6}$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl, aryl, heteroaryl,  $C_1$ - $C_6$ -alkyl aryl,  $C_1$ - $C_6$ -alkyl heteroaryl and mixtures thereof;

n is an integer from 0 to 3.

P

Claim 12 (New): A piperazine benzothiazole derivative according to claim 11, wherein  $R^{l}$  is hydrogen.

Claim 13 (New): A piperazine benzothiazole derivative according to claim 11, wherein R is selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>3</sub> alkyl, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl and mixtures thereof.

Claim 14 (New): A piperazine benzothiazole derivative according to claim 13, wherein R is H, or  $C_1$ - $C_3$  alkyl, in particular a methyl or an ethyl moiety, or  $C_1$ - $C_6$ -alkyl alkoxy.

Claim 15 (New): A piperazine benzothiazole derivative according to Claim 11, wherein n is 1.

Claim 16 (New): A piperazine benzothiazole derivative according to Claim 11 selected from the group consisting of:

1,3 benzothiazol-2-yl[2-({4-[(4-methylpiperazin-1-yl)methyl]benzyl}oxy)pyrimidin-4-yl]acetonitrile,

- 1,3 benzothiazol-2-yl[2-({4-[(4-benzyl-piperazin-1-yl)methyl]-benzyl}oxy)pyrimidin-4-y1]acetonitrile,
- 1,3 benzothiazol-2-yl(2-{[4-(piperazin-1-ylmethyl)benzyl]oxy}pyrimidin-4-yl)acetonitrile,
- $1, 3-benzothiazol-2-yl[2-(\{4-[(4-formylpiperazin-1-yl)methyl]benzyl\}oxy) pyrimidin-4-yl] acetonitrile,\\$
- [2-({4-[(4-acetylpiperazin-1-yl)methyl]benzyl}oxy)pyrimidin-4-yl](1,3-benzothiazol-2-yl)acetonitrile,
- (3H-Benzothiazol-2-ylidene)-{2-[4-(4-[1,2,4]oxadiazol-3-ylmethyl-piperazin-l-ylmethyl)-benzyloxy]-pyrimidin-4-yl}-acetonitrile,
- 4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazine-l-carboxylic acid methyl ester,
- 2-[4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazin-l-yl]-acetamide,
- (2-{4-[4-(2-Amino-acetyl)-piperazin-1-ylmethyl]-benzyloxy}-pyrimidin-4-yl)-(3H-benzothiazol-2-ylidene)-acetonitrile,
- [4-(4-{4-[(3H-Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazin-1-yl]-acetic acid methyl ester,
- (3H-Benzothiazol-2-ylidene)-(2-{4-[4-(2-methoxy-ethyl)-piperazin-1-yhmethyl]-benzyloxy}-pyrimidin-4-yl)-acetonitrile,
- 4-(4-{4-[(3H Benzothiazol-2-ylidene)-cyano-methyl]-pyrimidin-2-yloxymethyl}-benzyl)-piperazine-1-carboxylic acid dimethylamide,
- (3H-Benzothiazol-2-ylidene)-{2-[4-(4-ethyl-piperazin-1-ylmethyl)-benzyloxy]-pyrimidin-4-yl}-acetonitrile,

(3H-Benzothiazol-2-ylidene)-(2-{4-[4-(2-hydroxy-ethyl)-piperazin-1-ylmethyl]-benzyloxy}-pyrimidin-4-yl)-acetonitrile and mixtures thereof.

Claim 17 (New): A piperazine benzothiazole derivative according to Claim 11 for use as a medicament.

Claim 18 (New): A process for the manufacture of a medicament for the treatment of cerebral ischemic disorders or CNS disorders comprising adding a piperazine benzothiazole derivative according to Claim 11 to said medicament.

Claim 19 (New): Process for the preparation of a piperazine benzothiazole derivative according to Claim 11, comprising the following step:

whereby R,  $R^1$  and n are as above described.